Petros Pharmaceuticals Inc (NASDAQ: PTPI) is a healthcare technology company that is developing a proprietary SaaS and Software as a Medical Device platform designed to assist pharmaceutical companies in switching prescription drugs to over-the-counter products. The company's intended revenue model is technology licensing, out-licensing its platform to pharmaceutical brand owners and OTC commercial licensees rather than generating revenue from drug manufacturing or distribution. Petros was incorporated in Delaware on May 14, 2020, through a merger involving Neurotrope Inc. and Metuchen Pharmaceuticals LLC. Prior to June 2025, the company commercialized Stendra, an FDA-approved PDE-5 inhibitor, through subsidiaries that included Timm Medical Technologies Inc. and Pos-T-Vac LLC. As of the 10-K filed April 15, 2026, the company had divested its historical pharmaceutical commercial operations and the SaaS and SaMD platform remained in early development stages, with no disclosed licensing revenue. The platform is designed around the FDA's Nonprescription Drug Product with an Additional Condition for Nonprescription Use rule.

Revenue model

Technology licensing: the company intends to out-license its proprietary SaaS and SaMD platform to pharmaceutical companies and OTC licensees, with licensees bearing production and supply chain costs. As of the 10-K filed April 15, 2026, the platform was in early development and no licensing revenue was disclosed.

Products and services

Proprietary integrated technology platform with two components: (1) a SaaS tool designed to help pharmaceutical companies operationalize Rx-to-OTC switches under the FDA ACNU Rule, and (2) a Software as a Medical Device component intended as a consumer-facing interface for product self-selection. Historically, the company commercialized Stendra (avanafil), an FDA-approved PDE-5 inhibitor prescription medication. As of the 10-K filed April 15, 2026, the platform was in early development stages.

Customers and end markets

Target customers are pharmaceutical brand owners with prescription drug portfolios seeking Rx-to-OTC switches, and exclusive OTC commercial licensees. Secondary targets include self-care consumer companies and health technology companies combining digital platforms with OTC treatment solutions.

Value-chain role

Technology platform developer and licensor. The company is positioned as a provider of regulatory and commercialization technology for Rx-to-OTC transitions, with licensees responsible for drug manufacturing and supply chain. The company operates a virtual technology infrastructure and does not directly distribute or market medication as of the 10-K filed April 15, 2026.

Source: SEC 10-K, filed 2026-04-15

Industry: Pharmaceutical Preparations Peers: Adial Pharmaceuticals Inc AGILE THERAPEUTICS INC Aytu Biopharma Inc Barrel Energy Inc. Cingulate Inc GB SCIENCES INC Hoth Therapeutics Inc Johnson & Johnson